AstraZeneca PLC
AZN
$192.15
-$0.35-0.18%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.05% | 5.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.05% | 5.08% | |||
| Cost of Revenue | 13.54% | 9.45% | |||
| Gross Profit | -0.53% | 4.14% | |||
| SG&A Expenses | 2.35% | 4.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 159.55% | -23.61% | |||
| Total Operating Expenses | 5.44% | 5.10% | |||
| Operating Income | -8.60% | 5.02% | |||
| Income Before Tax | -18.96% | 3.74% | |||
| Income Tax Expenses | -57.69% | 4.42% | |||
| Earnings from Continuing Operations | -8.13% | 3.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | -200.00% | |||
| Net Income | -8.17% | 3.39% | |||
| EBIT | -8.60% | 5.02% | |||
| EBITDA | -21.07% | 6.87% | |||
| EPS Basic | -8.17% | 3.32% | |||
| Normalized Basic EPS | -8.30% | 6.71% | |||
| EPS Diluted | -8.50% | 3.20% | |||
| Normalized Diluted EPS | -8.42% | 6.63% | |||
| Average Basic Shares Outstanding | 0.00% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.13% | |||
| Dividend Per Share | -- | -100.00% | |||
| Payout Ratio | -- | 154.85% | |||